Unleashing the Power of Immune Cells: A Revolutionary Approach to Tumor Elimination
Imagine a future where our immune system becomes the ultimate weapon against cancer, a future free from the constraints of resistance and exhaustion. This vision is now one step closer to reality thanks to a groundbreaking study led by researchers at Weill Cornell Medicine.
The study, published in Nature Immunology, has unveiled a molecular secret that tumors have been exploiting to wear down the very immune cells designed to destroy them. But here's the game-changer: by silencing this signal, we can potentially revive the body's natural immunity, offering a new lease of life to immune-based therapies.
"Our goal is to make immune-based treatments accessible to every patient. To overcome resistance, we must awaken the potential of exhausted T cells, empowering them to wage war on cancer. This discovery paves the way for a future where the immune system becomes the ultimate tumor-fighting force," said Dr. Taha Merghoub, co-senior author and Margaret and Herman Sokol Professor in Oncology Research.
Immunotherapy has revolutionized cancer care, harnessing the body's immune system to fight tumors. However, many patients still face challenges, with initial responses fading as immune cells become exhausted. "Our findings reveal a novel mechanism by which tumors suppress the immune system," added Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center.
T cell exhaustion, triggered by prolonged exposure to chronic infections or tumors, is a complex phenomenon. These embattled immune cells, while capable of recognizing their foes, cease to attack. "They're primed but no longer killing," explained Dr. Merghoub. "This cellular surrender, though seemingly counterintuitive, acts as a protective brake against uncontrolled inflammation and sepsis."
Previous research has highlighted the role of PD1, a protein on the surface of T cells, in putting the brakes on immune response. Checkpoint-inhibitor drugs targeting PD1 have shown remarkable success in reviving T cells to combat cancers like melanomas.
The researchers set out to investigate another potential brake: CD47 molecules present on cancer cells. Previous studies suggested that CD47 could instruct immune cells to stand down, earning it the nickname "don't eat me signal."
However, the researchers made a surprising discovery. CD47 has a dual function, also present on the surface of T cells. "When T cells are activated, they express CD47. And when they get exhausted, they increase CD47 to very high levels," Dr. Merghoub revealed.
Experiments with mice lacking CD47 showed delayed tumor growth, suggesting that CD47 on immune cells, rather than cancer cells, was the culprit. The researchers suspected that eliminating CD47 on T cells could be beneficial. Indeed, T cells lacking CD47 were more effective at fighting melanoma in mice.
The researchers then turned their attention to how cancer cells coopt T-cell CD47 to promote exhaustion. They focused on thrombospondin-1, a large protein that interacts with CD47 and is produced by metastatic cancer cells. When they tested mice lacking thrombospondin-1, they found that T cells were less exhausted. "That was our eureka moment," said Dr. Merghoub. "It showed us that CD47 and thrombospondin are key players."
To understand this interaction better, the researchers used the TAX2 peptide to disrupt the interaction between CD47 and thrombospondin-1 in mouse tumor models. Their suspicions were confirmed: TAX2 preserved T-cell function and slowed down tumor progression in mice with melanoma or colorectal tumors. The T cells in treated mice were more active, produced more immune-boosting cytokines, and were better at infiltrating tumors.
"We used TAX2 as a proof-of-concept to confirm that disrupting the crosstalk between TSP-1 and CD47 prevents T cell exhaustion in mice with tumors," said Dr. Chien-Huan (Gil) Weng, the study's lead author. "Next, we plan to delve deeper into both upstream and downstream modulators that regulate this pathway and develop safe and effective ways to disrupt it, enhancing T cell-based cancer immunotherapy."
Targeting this interaction not only offers a valuable therapeutic approach but also has the potential to preserve tumor-reactive T cells in patients who develop resistance to current T cell-based immune checkpoint inhibitors. Even more promising, experiments suggest that blocking both PD1 and CD47 produces T cells that are more effective at killing cancer cells, said Dr. Merghoub. "We plan to explore this therapeutic angle further."
This research was funded by various organizations, including the National Institutes of Health, the National Cancer Institute, the Department of Defense, the Swim Across America, and the Parker Institute for Cancer Immunotherapy, among others.
